• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    S&P 500 Edges Lower; ADT Posts Upbeat Earnings

    2/28/24 2:30:04 PM ET
    $ADIL
    $ADT
    $IAS
    $INGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Diversified Commercial Services
    Consumer Discretionary
    Get the next $ADIL alert in real time by email

    U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 100 points on Wednesday.

    The Dow traded down 0.27% to 38,867.91 while the NASDAQ fell 0.50% to 15,954.75. The S&P 500 also fell, dropping, 0.18% to 5,068.92.

    Check This Out: Robinhood, Shake Shack And 2 Other Stocks Insiders Are Selling

     

    Leading and Lagging Sectors

     

    Real estate shares rose by 1.4% on Wednesday.

    In trading on Wednesday, communication services shares fell by 0.8%.

     

    Top Headline

     

    ADT Inc. (NYSE:ADT) reported better-than-expected earnings for its fourth quarter on Wednesday.

    ADT posted fourth-quarter fiscal 2023 sales decline of 7.2% year-on-year to $1.22 billion, missing the consensus of $1.44 billion. Adjusted EPS was 25 cents, beating the consensus of 4 cents.

    ADT expects CSB segment revenue of 4.8 billion-$5.0 billion. The company expects adjusted EPS of $0.60 – $0.70, against consensus of $0.50.

     

    Equities Trading UP

     

    Vivani Medical, Inc. (NASDAQ:VANI) shares shot up 274% to $3.78 after the company announced preclinical data on weight loss effects for NPM-115 and disclosed that semaglutide is the active pharmaceutical ingredient in NPM-139.

    Shares of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) got a boost, surging 159% to $2.1917. Adial Pharmaceuticals secured new US patent covering lead product for alcohol use disorder.

    vTv Therapeutics Inc. (NASDAQ:VTVT) shares were also up, gaining 117% to $18.05 after the company announced a $51 million private placement from healthcare-focused institutional investors and the JDRF T1D Fund.

     

    Equities Trading DOWN

     

    Oragenics, Inc. (NYSE:OGEN) shares dropped 42% to $1.42. Oragenics priced its public offering 1.4 million common shares at $1.50 per share for gross proceeds of $2.1 million.

    Shares of Integral Ad Science Holding Corp. (NASDAQ:IAS) were down 42% to $9.92 after the company reported fourth-quarter financial results.

    Inogen, Inc. (NASDAQ:INGN) was down, falling 35% to $6.08 following weak quarterly results.

    Also Check This Out: Top 3 Energy Stocks That Could Sink Your Portfolio In Q1

     

    Commodities

     

    In commodity news, oil traded down 0.3% to $78.65 while gold traded down 0.2% at $2,040.40.

    Silver traded fell 0.5% to $22.645 on Wednesday while copper fell 0.3% to $3.8390.

     

    Euro zone

     

    European shares were mostly lower today. The eurozone’s STOXX 600 fell 0.35%, London’s FTSE 100 fell 0.76% while Spain’s IBEX 35 Index fell 0.45% The German DAX gained 0.25% French CAC 40 rose 0.08% while Italy’s FTSE MIB Index declined 0.27%.

    The services confidence indicator in the Eurozone fell to 6 in February, the lowest in three months, while economic sentiment indicator fell to 95.4 in February. The consumer confidence indicator in the Eurozone increased by 0.6 points to a reading of -15.5 in February.

     

    Asia Pacific Markets

     

    Asian markets closed lower on Wednesday, with Japan’s Nikkei 225 falling 0.08%, Hong Kong’s Hang Seng Index dipping 1.51%, China’s Shanghai Composite Index tumbling 1.91% and India’s S&P BSE Sensex falling 1.08%.

    Hong Kong’s GDP increased by 4.3% year-over-year in the fourth quarter, up from a 4.1% increase in the prior period. The index of leading economic indicators in Japan was revised higher to 110.2 in December versus preliminary reading of 110, while index of coincident economic indicators was revised lower to 115.9 in December versus a flash reading of 116.2.

     

    Economics

     

    U.S. mortgage applications fell by 5.6% on the week ending Feb. 23.

    The U.S. economy grew an annualized 3.2% in the fourth quarter, versus a 4.9% rate in the previous quarter.

    The U.S. trade deficit in goods rose to $90.20 billion in January versus a revised $87.89 billion in the prior month.

    U.S. wholesale inventories declined by 0.1% month-over-month in January following a 0.4% increase a month ago.

    U.S. crude oil inventories increased by 4.199 million barrels in the week ending Feb. 23, versus market estimates of a 2.743 million gain, the EIA said.

    Now Read This: Cramer Says This AI Stock Is Just An Nvidia Play, Prefers This Stock Over Anheuser-Busch

    Get the next $ADIL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADIL
    $ADT
    $IAS
    $INGN

    CompanyDatePrice TargetRatingAnalyst
    vTv Therapeutics Inc.
    $VTVT
    1/23/2026$58.00Buy
    Roth Capital
    vTv Therapeutics Inc.
    $VTVT
    1/5/2026$67.00Buy
    TD Cowen
    vTv Therapeutics Inc.
    $VTVT
    11/19/2025$40.00Buy
    BTIG Research
    Inogen Inc
    $INGN
    6/16/2025$14.00Buy
    B. Riley Securities
    Inogen Inc
    $INGN
    5/22/2025$12.00Hold → Buy
    Needham
    ADT Inc.
    $ADT
    4/4/2025$9.00Underweight → Equal Weight
    Barclays
    Integral Ad Science Holding Corp.
    $IAS
    3/28/2025$16.00 → $9.00Outperform → Neutral
    Robert W. Baird
    Integral Ad Science Holding Corp.
    $IAS
    12/5/2024$10.00Sector Perform
    Scotiabank
    More analyst ratings

    $ADIL
    $ADT
    $IAS
    $INGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Gregg bought $1,999,999 worth of shares (1,351,351 units at $1.48) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    1/28/26 10:01:22 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Williams Gregg bought $1,983,334 worth of shares (1,737,765 units at $1.14) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    1/20/26 9:00:37 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Mendelsohn Aaron gifted 20,000 shares and bought $24,600 worth of shares (20,000 units at $1.23) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    12/31/25 9:00:39 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ADIL
    $ADT
    $IAS
    $INGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Gregg bought $1,999,999 worth of shares (1,351,351 units at $1.48) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    1/28/26 10:01:22 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: Director Telling Fred sold $198 worth of shares (210 units at $0.94), decreasing direct ownership by 18% to 948 units (SEC Form 4)

    4/A - ORAGENICS INC (0001174940) (Issuer)

    1/22/26 1:04:30 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Williams Gregg bought $1,983,334 worth of shares (1,737,765 units at $1.14) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    1/20/26 9:00:37 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ADIL
    $ADT
    $IAS
    $INGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on vTv Therapeutics with a new price target

    Roth Capital initiated coverage of vTv Therapeutics with a rating of Buy and set a new price target of $58.00

    1/23/26 8:21:38 AM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on vTv Therapeutics with a new price target

    TD Cowen initiated coverage of vTv Therapeutics with a rating of Buy and set a new price target of $67.00

    1/5/26 8:58:53 AM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on vTv Therapeutics with a new price target

    BTIG Research initiated coverage of vTv Therapeutics with a rating of Buy and set a new price target of $40.00

    11/19/25 8:58:53 AM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ADT
    $IAS
    $INGN
    SEC Filings

    View All

    Adial Pharmaceuticals Inc filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)

    2/4/26 4:30:34 PM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    vTv Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - vTv Therapeutics Inc. (0001641489) (Filer)

    2/2/26 4:18:28 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vivani Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Vivani Medical, Inc. (0001266806) (Filer)

    1/27/26 4:11:14 PM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ADIL
    $ADT
    $IAS
    $INGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

    NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600:  S&P MidCap 400 constituent Ciena Corp. (NYSE:CIEN) will replace Dayforce Inc. (NYSE:DAY) in the S&P 500, S&P SmallCap 600 constituent Arrowhead Pharmaceuticals Inc. (NASD: ARWR) will replace Ciena in the S&P MidCap 400, and ADT Inc. (NYSE:ADT) will replace Arrowhead Pharmaceuticals in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 9. Thoma Bravo L.P. acquired Dayforce in a deal that closed today.OneSpaWorld Holdings Ltd. (NASD: OSW) will replace Dynavax Technologies Corp. (NASD: DVAX) in the S&P SmallCap 600 effec

    2/4/26 6:15:00 PM ET
    $ADT
    $ARWR
    $CIEN
    Diversified Commercial Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04

    GLEN ALLEN, Va., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today applauded the passage by Congress and signing into law by President Donald J. Trump of the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Bill, 2026. The final legislation incorporates Senate Report 119-55, which includes a significant Congressional directive to the U.S. Food and Drug Administration (FDA) and the National Institute on Drug Abuse (NIDA) to collaborate on

    2/4/26 9:35:00 AM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

    GLEN ALLEN, Va., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will effect a 1-for-25 reverse stock split (the "Reverse Split") of its common stock, par value $0.001 per share ("Common Stock"), that will become effective on February 5, 2026 at 11:59 p.m. Eastern Time (the "Effective Time"). Adial's Common Stock will continue to trade on the Nasdaq Capital Market ("Nasdaq") under the symbol "ADIL" and will begin trading on a split-adjusted basis when the Nasdaq opens o

    2/3/26 4:05:00 PM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ADT
    $IAS
    $INGN
    Leadership Updates

    Live Leadership Updates

    View All

    Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

    NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600:  S&P MidCap 400 constituent Ciena Corp. (NYSE:CIEN) will replace Dayforce Inc. (NYSE:DAY) in the S&P 500, S&P SmallCap 600 constituent Arrowhead Pharmaceuticals Inc. (NASD: ARWR) will replace Ciena in the S&P MidCap 400, and ADT Inc. (NYSE:ADT) will replace Arrowhead Pharmaceuticals in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 9. Thoma Bravo L.P. acquired Dayforce in a deal that closed today.OneSpaWorld Holdings Ltd. (NASD: OSW) will replace Dynavax Technologies Corp. (NASD: DVAX) in the S&P SmallCap 600 effec

    2/4/26 6:15:00 PM ET
    $ADT
    $ARWR
    $CIEN
    Diversified Commercial Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ADT appoints Kim Miller as EVP & Chief Marketing & Communications Officer

    BOCA RATON, Fla., Dec. 22, 2025 (GLOBE NEWSWIRE) -- ADT Inc. (NYSE:ADT) today announced Kim Miller will join the company as Executive Vice President and Chief Marketing & Communications Officer. Miller will lead the development of a unified, and updated, go-to-market approach, leading customer acquisition strategies tied to performance marketing and underscored by disciplined growth. "Kim's appointment marks an exciting step in ADT's evolution. Her proven ability to unite brand, performance marketing, and customer experience will contribute towards accelerating growth and strengthening our position as the leader in smart home security," said Jim DeVries, ADT Chairman, President and CEO.

    12/22/25 9:00:00 AM ET
    $ADT
    Diversified Commercial Services
    Consumer Discretionary

    IAS APPOINTS MELISSA FURZE AS HEAD OF DATA SCIENCE

    Former LinkedIn executive to scale IAS's data science and AI capabilities worldwide NEW YORK, Dec. 22, 2025 /PRNewswire/ -- Integral Ad Science (NASDAQ:IAS), a leading global media measurement and optimization platform, today announced that Melissa Furze joined the company as Head of Data Science at IAS reporting to the Chief Technology Officer. Melissa will lead the company's global data science, AI, and analytics strategy, partnering closely with product, engineering, and the commercial teams to accelerate innovation, strengthen protection and performance capabilities, and deliver trusted, data-driven outcomes for advertisers and publishers worldwide.

    12/22/25 8:00:00 AM ET
    $IAS
    Computer Software: Programming Data Processing
    Technology

    $ADIL
    $ADT
    $IAS
    $INGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Oragenics Inc.

    SC 13G/A - ORAGENICS INC (0001174940) (Subject)

    11/14/24 7:29:57 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Integral Ad Science Holding Corp.

    SC 13G/A - INTEGRAL AD SCIENCE HOLDING CORP. (0001842718) (Subject)

    11/14/24 6:19:26 PM ET
    $IAS
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SC 13G/A filed by ADT Inc.

    SC 13G/A - ADT Inc. (0001703056) (Subject)

    11/14/24 4:35:38 PM ET
    $ADT
    Diversified Commercial Services
    Consumer Discretionary

    $ADIL
    $ADT
    $IAS
    $INGN
    Financials

    Live finance-specific insights

    View All

    Inogen Announces Preliminary Revenue Results for Fourth Quarter and Full-Year 2025

    Inogen to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced preliminary, unaudited revenue results for the quarter and year ended December 31, 2025. The Company estimates preliminary, unaudited total revenue in the fourth quarter of 2025 to be approximately $82 million, representing year-over-year growth of approximately 2%. Full year 2025 total preliminary, unaudited revenue is expected to be approximately $349 million, representing year-over-year growth of approximately 4%. For the full year 2025, the Com

    1/12/26 8:30:00 AM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen Announces Third Quarter 2025 Financial Results

    Delivered seventh consecutive quarter of mid-single-digit revenue growth Reiterating full-year revenue guidance Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended September 30, 2025. Recent Highlights $92.4 million revenue, a year-over-year increase of 4.0%, marking the seventh consecutive quarter of mid-single-digit percentage growth GAAP net loss of $5.3 million and adjusted net loss of $0.5 million compared to prior year GAAP net loss of $6.0 million and adjusted net loss of $2.6 million $2.3 million adjusted EBITDA, the third consecutive quart

    11/5/25 7:30:00 AM ET
    $INGN
    Industrial Specialties
    Health Care

    IAS Reports Third Quarter 2025 Financial Results

    Total revenue increased 16% to $154.4 million Net income of $7.0 million at a 5% margin; adjusted EBITDA increased to $55.3 million at a 36% margin  NEW YORK, Nov. 4, 2025 /PRNewswire/ -- Integral Ad Science (NASDAQ:IAS), a leading global media measurement and optimization platform, today announced financial results for the third quarter ended September 30, 2025. "We exceeded our revenue and adjusted EBITDA outlook for the third quarter with strength across our businesses," said Lisa Utzschneider, CEO of IAS. "We are focused on working towards closing the previously announced

    11/4/25 7:35:00 AM ET
    $IAS
    Computer Software: Programming Data Processing
    Technology